You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Resilient Wayside Structures to Reduce Severity of Passenger Equipment Collisions and Derailments

    SBC: PROTECTION ENGINEERING CONSULTANTS LLC            Topic: 171FR3

    Proposal title: Resilient Wayside Structures to Reduce Severity of Passenger Equipment Collisions and Derailments Additional passenger fatalities/injuries can occur during derailments involving interaction with wayside structures. Analogously, automobile fatalities often result from interaction of vehicles with roadside structures; personnel hazard reduction is a key design criterion for roadsid ...

    SBIR Phase II 2018 Department of Transportation
  2. Development of Taenia Solium Specific Aptamers for Diagnostic Assays

    SBC: Lynntech Inc.            Topic: ODCDC

    The parasitic tapeworm Taenia solium causes two diseasestaeniasisadult worm in the intestineand cysticercosistissue infection by the cystwhich can lead to seizuresThe Tsolium life cycle involves both humans and pigshowever humans are the only definitive host for the adult Tsolium tapewormDiagnosing people infected with the adult worm is a critical step toward eliminating Tsolium althogetherHowever ...

    SBIR Phase I 2018 Department of Health and Human Services
  3. Topic 346: Targeted Radionuclide Therapy of Neuroendocrine Tumors Using 212Pb-octreotate Analogs

    SBC: RADIOMEDIX, INC.            Topic: NCI

    A peptide receptor radionuclide therapy (PRRT) using [177Lu]/[90Y]-labeled somatostatin analogs has been proven to induce objective response in 30-45% of patients with advanced/progressive neuroendocrine tumors (NETs). The complete response to beta-emitter PRRT is rare. This is due to the fact that NETs are diagnosed at late stage of disease; the NETs patients with remissions could develop resista ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Topic 375: 18F PET Tracer For Imaging PD-L1 (Moonshot)

    SBC: SIBTECH, INC.            Topic: NCI

    New therapies, designed to enhance anti-tumor immunity are based on the blockade of the checkpoint components, either PD-1 on immune cells or PD-L1 on tumor cells. This strategy, while being spectacularly successful in some patients for some cancers, fails for many other patients. The expression of PD-L1 is highly dynamic and its prevalence within tumors can vary significantly over time. The curre ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Topic 379: Extensible and Scalable Platform for Data Integration from Wearable Sensors to Generate Novel Analytics for Cancer Patients

    SBC: Litmus Health, Inc.            Topic: NCI

    The longterm objective of the Litmus Health platform is to allow researchers and clinicians to use data on cancer patients from wearables/sensors and smartphones. Collecting real-time, high-quality data from patients will transform care and clinical trials. Automating data collection, storage, analysis, and interpretation of data will result in better measurement of signs and symptoms and improved ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Topic 372: Highly multiplexed selection of aptamers to hundreds of canine immunotherapy targets

    SBC: Base Pair Biotechnologies, Inc.            Topic: NCI

    The preclinical development of cancer therapeutics, including the recent trend and focus on cancer immunotherapies, is evolving from the traditional use of mouse models to the use of other animal models including canine, rat, and minipig. Each of these non-mouse models carries its own advantages and abilities to increase the clinical relevance of the model as compared to mouse models. Yet, the wid ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma

    SBC: ONCOARENDI THERAPEUTICS LLC            Topic: NHLBI

    Approximatelymillion Americans suffer from asthmawhich leads to aboutdeaths per yearand is responsible for estimated annual total direct and indirect costs of $billionDespite the existing treatments for asthmapredominantly combinations of inhaledagonists and corticosteroidsCSsthere remains a significant unmet medical need for new therapies which address two key issuesapproximatelyof patients are i ...

    SBIR Phase II 2018 Department of Health and Human Services
  8. Polyketide chiral building blocks and biocatalysts

    SBC: Coala Biosciences            Topic: 300

    PROJECT SUMMARY As with most synthetic chemistsCoALA Biosciences is inspired by naturally occurring polyketide assembly lineswhich synthesize diverse medicines through reactions that generate carbon carbon bonds and precisely set stereocentersIf chemists were to collaborate with the enzymes in these assembly linessyntheses of compounds in the drug discovery process would be greatly accelerated and ...

    SBIR Phase I 2018 Department of Health and Human Services
  9. An antigen-detection assay to diagnose Babesia microti infection

    SBC: L2 DIAGNOSTICS, LLC            Topic: NIAID

    Project Summary Human babesiosis is a malaria like multisystem disease caused primarily by Babesia microtian emerging apicomplexan parasite that infects and develops within human erythrocytesThe parasite is transmitted to humans by the tick vector Ixodes scapularis and can also be introduced through blood transfusionInfection can cause flu like symptomsand severe infection can be fatalin particula ...

    SBIR Phase I 2018 Department of Health and Human Services
  10. Small molecule Inhibitors of steroid receptor coactivator to treat breast cancer

    SBC: Coactigon, Inc.            Topic: 102

    ABSTRACTSteroid Receptor CoactivatorSRCis a key breast cancer oncogene that is frequently overexpressed or amplified in estrogen receptorERand human epidermal growth factor receptorHERpositive breast cancersElevated expression of SRCalso has been associated with resistance to tamoxifen therapy and with poor disease outcome in HERpositive breast cancersNumerous studies have shown that experimental ...

    STTR Phase I 2018 Department of Health and Human Services
US Flag An Official Website of the United States Government